|1.||Wright, Rebecca A: 1 article (09/2002)|
|2.||Kelly, Gerald: 1 article (09/2002)|
|3.||Kingston, Ann E: 1 article (09/2002)|
|4.||Harris, John R: 1 article (09/2002)|
|5.||Johnson, Bryan G: 1 article (09/2002)|
|6.||Tizzano, Joseph T: 1 article (09/2002)|
|7.||Chamberlain, Mary-Jo: 1 article (09/2002)|
|8.||Johnson, Michael P: 1 article (09/2002)|
|9.||Tomlinson, Rosemarie: 1 article (09/2002)|
|10.||Griffey, Kelly: 1 article (09/2002)|
01/01/2000 - "In this study, LY393053 has also been evaluated electrophysiologically on native group I metabotropic glutamate receptors in an in vitro spinal cord preparation as well as behaviourally, in a mouse model of visceral pain. "
01/01/2000 - "By revealing a potent effect of LY393053 in antagonising the native group I metabotropic receptor-mediated responses in the spinal cord in rodents, and an antinociceptive efficacy in a mouse visceral pain model, these results, therefore, provide additional evidence in support of the analgesic potential of metabotropic glutamate receptor antagonists."
09/20/2002 - "All the compounds produced dose-dependent inhibition of group I mGlu receptor agonist (RS)-3,5-dihydroxyphenylglycine (DHPG)-induced limbic seizure responses in mice with ED(50) values ranging from 9 nmol for LY393053 to 138 nmol for LY339840 after intracerebroventricular injection and were more potent than the mGlu1 receptor antagonist 1-aminoindan-1,5-dicarboxylic acid (ED(50)=477 nmol). "
|1.||Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
|2.||2- methyl- 3- hydroxy- 4- carboxyphenylglycine